Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat

Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on “Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a”

(2013) Yumei Ye et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects

(2012) Betsy B. Dokken et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia

(2012) Jacob Lønborg et al.   Circulation-Cardiovascular Interventions

Antiapoptotic Actions of Exendin-4 against Hypoxia and Cytokines Are Augmented by CREB

(2012) Kalpana Velmurugan et al.   ENDOCRINOLOGY

Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms

(2012) Yochai Birnbaum et al.   Metabolic Syndrome and Related Disorders

Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca

(2012) Susana Ravassa et al.   Endocrinologia y Nutricion

Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway

(2011) Yong-Fu Xiao et al.   Cardiovascular Diabetology

Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents

(2011) B. B. Dokken et al.   HORMONE AND METABOLIC RESEARCH

DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion

(2011) Hui-Chun Ku et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

(2011) Weike Bao et al.   PLoS One

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

(2010) Que Liu et al.   Cardiovascular Diabetology

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

(2010) Mark Fineman et al.   CLINICAL PHARMACOKINETICS

Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon

(2010) A. Walker et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

(2009) Leo Timmers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

New treatments in type 2 diabetes: a focus on the incretin-based therapies

(2008) Anthony H. Barnett   CLINICAL ENDOCRINOLOGY

In Vivo Activation of Peroxisome Proliferator-Activated Receptor-  Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats

(2008) T.-L. Yue et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

(2008) L. J. Holt et al.   PROTEIN ENGINEERING DESIGN & SELECTION